Cash/Burn From SEC Filing For Period: 

Q1 '20

TGTX

TG Therapeutics

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases.

Cash

$78.3M

Burn Rate

-$51.1M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Ublituximab + Ibrutinib | GENUINE

R/R High Risk CLL

Phase 3

TBD

Umbra +/- Ublitux +/- Benda (UNITY-NHL)

R/R NHL

Phase 3

TBA

Umbra + Ublitux (UNITY-CLL)

Frontline & R/R CLL

Phase 3 (Regulatory Submission & Full Data Presentation)

Year-end 2020

Ublituximab (ULTIMATE 1 & 2)

Multiple Sclerosis

Phase 3 (Top-line Data)

H2 2020

TG-1101 and TG-1202 (UNITY)

Chronic Lymphocytic Leukemia (CLL) (FL & R/R)

Phase 3 (Regulatory Submission)

Year-end 2020

Umbralisib Monotherapy (UNITY-NHL)

R/R MZL & FL

Data Presentation

Q4 2020

Umbra + Ublitux + Vene (ULTRA-V)

CLL

Phase 2

TBD

TG-1801

CD47/CD19

Phase 1

TBD

TG-1701 (BTK Inhibitor)

B-Cell Malignancies

Phase 1

TBD

TG-1601

BET Inhibitor

Pre-Clinical

TBD

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon